Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
Completed
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Phase 3
2014-02-01
Background: A progressive decrease in Helicobacter pylori eradication rates has been
described over the years, so new combinations of antibiotics for treatment are needed.
Aim: To evaluate the efficacy and safety of the addition of rifaximin to standard triple
therapy (omeprazole, amoxicillin and clarithromycin) for the eradication of H. pylori.
Methods: Independent prospective pilot clinical trial (EUDRA CT: 2013-001080-23). Forty
consecutive adult patients were included with H. pylori infection, dyspeptic symptoms and
naive to eradication treatment. A full blood test was performed in the first 5 patients
included to evaluate the safety of the treatment. H. pylori eradication was confirmed with
urea breath test at least 4 weeks after the end of treatment. Treatment: Rifaximin 400 mg/8
h, clarithromycin 500 mg/12 h, amoxicillin 1 g/12 h, and omeprazole 20 mg/12 h for 10 days.
Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea
Completed
Bausch Health Americas, Inc.
Phase 2
2003-06-01
The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in
the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.
Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea
Completed
The University of Texas Health Science Center, Houston
Phase 2
2003-06-01
The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in
the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.
Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea
Completed
Valeant Pharmaceuticals International, Inc.
Phase 2
2003-06-01
The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in
the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
